title: Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats.
abstract: The second generation antipsychotic drugs are effective treatments for psychotic disorders. Many of these compounds, including the drug olanzapine, have been associated with metabolic side-effects, including weight gain, impaired glucose tolerance and insulin resistance, which increase the risk of developing cardiometabolic disorders. Rodent models of olanzapine-induced metabolic side-effects have been used to study the physiology of these effects, but only at a single time point after drug treatment. The purpose of the present study was to examine longitudinal changes with chronic antipsychotic drug treatment. Adult female rats were treated with either olanzapine (15 mg/kg) or vehicle for five consecutive days each week, followed by a 48 h washout period. Animals were then challenged with either olanzapine (15 mg/kg) or vehicle, and fasting glucose and insulin values were recorded, as well as glucose clearance in the glucose tolerance test. Treatment with olanzapine was continued for 10 weeks, with weekly tests of metabolic indices. Rats treated acutely with olanzapine showed both glucose dysregulation and insulin resistance; for the group treated during the week with olanzapine, these effects did not change by the end of ten weeks of treatment. However, in the group of animals challenged only once per week with olanzapine, the metabolic side-effects markedly intensified with the passage of time, whereby glucose intolerance and insulin resistance increased significantly compared to both baseline values and all other treatment groups. This previously unreported sensitization phenomenon represents a novel finding that may have clinical implications for patients receiving intermittent antipsychotic drug dosing or with variable adherence to treatment.
authors.affiliation: Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, B.C., Canada.
authors.forename: H N
authors.initials: HN
authors.lastname: Boyda
authors.forename: R M
authors.initials: RM
authors.lastname: Procyshyn
authors.forename: L
authors.initials: L
authors.lastname: Tse
authors.forename: D
authors.initials: D
authors.lastname: Wong
authors.forename: C C
authors.initials: CC
authors.lastname: Pang
authors.forename: W G
authors.initials: WG
authors.lastname: Honer
authors.forename: A M
authors.initials: AM
authors.lastname: Barr
mesh_terms: D000818:Animals; D001569:Benzodiazepines / Q000008:administration & dosage* / Q000633:toxicity*; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D004334:Drug Administration Schedule; D005260:Female; D018149:Glucose Intolerance / Q000139:chemically induced* / Q000378:metabolism*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D000077152:Olanzapine; D051381:Rats; D017207:Rats, Sprague-Dawley; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D007328:Insulin; D001569:Benzodiazepines; D000077152:Olanzapine